Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2014 Feb 18;289(13):9100–9112. doi: 10.1074/jbc.M114.553511

IQGAP1 Binds to Estrogen Receptor-α and Modulates Its Function*

Huseyin H Erdemir 1,1, Zhigang Li 1, David B Sacks 1,2
PMCID: PMC3979404  PMID: 24550401

Background: IQGAP1 is a scaffold protein that modulates diverse signaling pathways.

Results: IQGAP1 binds to estrogen receptor-α (ERα) and ERβ, and knockdown of IQGAP1 impairs 17β-estradiol (E2)-stimulated transcriptional activation in human breast epithelial cells.

Conclusion: IQGAP1 modulates ERα function and is required for maximal E2 function.

Significance: IQGAP1 might be a therapeutic target for patients with breast carcinoma.

Keywords: Cell Signaling, Estrogen, Estrogen Receptor, Nuclear Receptors, Protein-Protein Interactions, Scaffold Proteins, Transcription, IQGAP1

Abstract

The estrogen receptor (ER) is a steroid hormone receptor that acts as a transcription factor, modulating genes that regulate a vast range of cellular functions. IQGAP1 interacts with several signaling proteins, cytoskeletal components, and transmembrane receptors, thereby serving as a scaffold to integrate signaling pathways. Both ERα and IQGAP1 contribute to breast cancer. In this study, we report that IQGAP1 binds ERα and ERβ. In vitro analysis with pure proteins revealed a direct interaction between IQGAP1 and ERα. Investigation with multiple short fragments of each protein showed that ERα binds to the IQ domain of IQGAP1, whereas the hinge region of ERα is responsible for binding IQGAP1. In addition, IQGAP1 and ERα co-immunoprecipitated from cells, and the association was modulated by estradiol. The interaction has functional effects. Knockdown of endogenous IQGAP1 attenuated the ability of estradiol to induce transcription of the estrogen-responsive genes pS2, progesterone receptor, and cyclin D1. These data reveal that IQGAP1 binds to ERα and modulates its transcriptional function, suggesting that IQGAP1 might be a target for therapy in patients with breast carcinoma.

Introduction

The estrogen receptor (ER)3 participates in a diverse range of biological functions, including cell proliferation, apoptosis, migration and differentiation (1). Humans have two isoforms of ER, termed α and β, which are expressed from different genes (2). ERα and ERβ contain analogous structural and functional domains, including the ligand-independent transcriptional activation function-1 located in regions A and B, a DNA-binding domain (DBD) in region C, a hinge region (region D), and hormone-binding domain/ligand-dependent activation function-2 (region E). Notwithstanding these similarities, the receptors differ in both their tissue distribution and functions (1, 2). 17β-Estradiol (E2) binding to the ligand-binding domain of ERα can produce distinct effects in the target cells by stimulating two pathways. These are the “classic” pathway in the nucleus that enhances gene transcription and extranuclear actions that are initiated from ERα in the plasma membrane and result in rapid actions of E2 by activating signaling pathways (3). In the classic pathway, E2 induces a change in ERα conformation, resulting in dimerization of the receptor. In the nucleus, the E2-ERα complex binds either directly to estrogen response elements in the promoters of target genes or indirectly through protein-protein interactions with other transcription factor complexes like Fos-Jun (activator protein-1 response elements) and influences transcription of genes that lack estrogen response elements (2, 4). Multiple ERα target genes have been identified, including activator protein-1 (5), specific protein-1 (6), progesterone receptor (PR) (7), and pS2/trefoil factor 1 (8).

Distinct co-regulatory proteins are recruited to ERα and modulate ERα function by serving as co-repressors or co-activators (2). Accumulating evidence reveals that ERα associates with interconnected networks of proteins that maintain the structure and function of the receptor and influence estrogen-responsive gene expression (9). One of the proteins that interact with ERα is the Ca2+ signaling protein calmodulin. Prior work from our laboratory characterized the interaction between ERα and calmodulin. We demonstrated that calmodulin binds directly to ERα in a Ca2+-regulated manner (10). Calmodulin binding promotes the stability of ERα by sequestering it away from the ubiquitin-proteasome pathway (11). Interestingly, calmodulin is also necessary for E2-stimulated transcriptional activation of ERα (12). Thus, specific cellular proteins can influence ERα degradation and transcriptional activity.

IQGAP1 is a ubiquitously expressed scaffold protein that associates with a wide repertoire of binding partners. Almost 100 proteins have been identified that interact with IQGAP1 either directly or in a multiprotein complex (13, 14). These range from signaling proteins and small GTPases to cytoskeletal components and kinases (1315). IQGAP1 also binds to and regulates the function of selected growth factor receptors, such as human epidermal growth factor receptor-2 (16), epidermal growth factor receptor (17), fibroblast growth factor receptor (18) and vascular endothelial growth factor receptor-2 (19).

ERα target gene expression results from the coordinated action of ERα and its co-regulators (4). Most of these co-regulatory proteins contain an LXXLL motif (L, leucine; X, any amino acid) that interacts with the ligand-binding domain of ERα (20). Inspection of the amino acid sequence of human IQGAP1 revealed three LXXLL motifs, raising the possibility that IQGAP1 might bind ERα. In this study, we demonstrated that IQGAP1 and ERα associate in vitro and co-immunoprecipitate from cells. Binding was regulated by E2, and the ability of E2 to induce transcriptional activation was impaired in cells in which IQGAP1 was specifically knocked down by siRNA.

EXPERIMENTAL PROCEDURES

Materials

MCF-7, T47D, and HEK293 cells were obtained from the American Type Culture Collection. All reagents for tissue culture were bought from Invitrogen. Protein A-Sepharose and glutathione-Sepharose were purchased from GE Healthcare. Anti-FLAG affinity gel was from Sigma-Aldrich. PVDF membranes were purchased from Millipore Corp. Anti-ERα polyclonal and monoclonal antibodies, anti-ERβ polyclonal antibodies, anti-FLAG monoclonal antibody, rabbit IgG, and mouse IgG were obtained from Santa Cruz Biotechnology. Anti-IQGAP1 polyclonal antibodies have been characterized previously (21). Blocking buffer and infrared dye-conjugated (IRDye) antibodies, both anti-mouse and anti-rabbit, were obtained from LI-COR Biosciences. Recombinant human ERα and ERβ were purchased from Invitrogen.

Plasmid Construction and Expression

The construction of myc-tagged IQGAP1, IQGAP1-N (N-terminal half of IQGAP1; amino acids 2–863), IQGAP1-C (C-terminal half of IQGAP1; amino acids 864–1657), IQGAP1ΔIQ (amino acids 764–863 deleted), and IQGAP1-IQ (IQ region of IQGAP1; amino acids 717–916) was detailed previously (21, 22). FLAG-tagged ERβ was purchased from Addgene (plasmid 35562, deposited by Harish Srinivas) (23). myc-tagged ERα, ERα(1–270), ERα(300–595), ERα(180–595), and ERα(180–353) were described previously (12).

To generate ERα deletion constructs, amino acids were deleted from myc-tagged ERα using primers 5′-CGGCTCCGCAAATGCTACGAAG-3′ (forward) and 5′-GTAGCGAGTCTCCTTGGCAG-3 (reverse) for deletion of amino acids 185–240 (ERαΔ185–240), 5′-ACGGCCGACCAGATGGTCAGTGCC-3′ (forward) and 5′-GCAGGCCTGGCAGCTCTTCC-3′ (reverse) for deletion of amino acids 240–311 (ERαΔ240–311), 5′-AGAGATGATGGGGAGGGCAGG-3′ (forward) and 5′-GCAGGCCTGGCAGCAGCTCTTCC-3′ (reverse) for deletion of amino acids 240–270 (ERαΔ240–270), and 5′-ACGGCCGACCAGATGGTCAGTGCC-3′ (forward) and 5′-GCGCTTGTGTTTCAACATTCTCCC-3 (reverse) for deletion of amino acids 270–311 (ERαΔ270–311). To construct GST-ERα, PCR was performed using pcDNA3-myc-ERα as a template with 5′-CGGGATCCACCATGACCCTCCACACC-3′ (forward) and 5′-GAGGGCCCTCAGACTGTGGCAGGGAAACC-3′ (reverse) primers. The product was digested with BamHI and inserted into pGEX4T-TEV at BamHI and SmaI sites. The sequences of all plasmids were confirmed by DNA sequencing. Plasmids were purified with a QIAprep Spin Miniprep kit (Qiagen).

Preparation of Fusion Proteins

GST-IQGAP1 was expressed in Escherichia coli and isolated using glutathione-Sepharose chromatography essentially as described previously (21). Where indicated, IQGAP1 was further purified by cleaving GST using tobacco etch virus (22). GST-ERα was expressed and isolated as described for GST-IQGAP1. The size and purity of the GST proteins were evaluated by SDS-PAGE and Coomassie staining. All proteins were at least 90% pure.

In Vitro Binding Assays

Purified untagged IQGAP1 (1 μg) was incubated with 4 μg of GST alone or 4 μg of GST-ERα on glutathione-Sepharose beads in 500 μl of Buffer A (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, and 1% Triton X-100) with protease and phosphatase inhibitors (Thermo Scientific) and 1 mm phenylmethylsulfonyl fluoride (PMSF) (Buffer B) for 3 h at 4 °C. After washing the beads five times with Buffer A, samples were resolved by SDS-PAGE. The gel was cut at the 100-kDa region. The top part of the gel was transferred to PVDF, blocked with Blocking Buffer (LI-COR Biosciences) for 1 h at 22 °C, and then probed with anti-IQGAP1 polyclonal antibodies overnight at 4 °C. The membrane was incubated with IRDye-conjugated anti-rabbit antibody for 1 h, and antigen-antibody complexes were detected using the Odyssey imaging system (LI-COR Biosciences). The lower portion of the gel containing GST and GST-ERα was stained with Coomassie Blue.

For GST-IQGAP1 pulldown, recombinant human ERα (1 μg) was incubated with 1 μg of GST or 1 μg of GST-IQGAP1 on glutathione-Sepharose beads in Buffer B for 3 h at 4 °C. After washing the beads five times with Buffer A, samples were resolved by SDS-PAGE, and the gel was cut at both the 37- and 100-kDa regions. The top and bottom portions of the gel containing GST-IQGAP1 and GST, respectively, were stained with Coomassie Blue. The middle portion of the gel was transferred to PVDF and processed for Western blotting with anti-ERα monoclonal antibody and IRDye-conjugated anti-mouse antibody. GST-IQGAP1 pulldown of recombinant human ERβ was performed essentially as described for ERα except that the blots were probed with anti-ERβ antibody.

Cell Culture and Transfection

HEK293 and MCF-7 cells were maintained in DMEM, and T47D cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium. Both media were supplemented with 10% FBS and 1% penicillin/streptomycin. HEK293 cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Transient overexpression of IQGAP1 increased the amount of the protein in cell lysates by 1.95 ± 0.23-fold (mean ± S.E., n = 5).

GST Pulldown Assays

MCF-7 and T47D cells were plated in 10-cm dishes. When they reached 90% confluence, cells were washed twice with ice-cold PBS (155.6 mm NaCl, 1 mm KH2PO4, and 2.9 mm Na2HPO4, pH 7.4) and lysed with 500 μl of Buffer B. Lysates were processed by sonication for 10 s with a Model 100 Dismembrator (Fischer Scientific), and insoluble material was pelleted by centrifugation for 10 min. The resultant supernatants were precleared by incubating with glutathione-Sepharose beads for 1 h at 4 °C. Equal amounts of protein lysate were incubated with 4 μg of GST, GST-ERα, or GST-IQGAP1 for 3 h at 4 °C. After centrifugation, samples were washed five times with Buffer A and separated by SDS-PAGE. The gel was cut at the 100- and 37-kDa regions. For GST-IQGAP1 pulldown, the top and bottom portions containing GST-IQGAP1 and GST proteins, respectively, were stained with Coomassie Blue. The middle part of the gel was transferred to PVDF. For GST-ERα pulldown, the gel was cut at 100 kDa. The bottom portion of the gel was stained with Coomassie, and the top portion was transferred to PVDF. After transferring to PVDF, samples were processed by Western blotting.

Transcription and Translation (TnT) Product Production and Binding Analysis

[35S]Methionine-labeled TnT products were synthesized using the TnT Quick Coupled Transcription/Translation system (Promega) essentially as described previously (16). Briefly, 1 μg each of pcDNA3-IQGAP1, IQGAP1-N, IQGAP1-C, IQGAP1-IQ, IQGAP1ΔIQ, ERα, ERα(2–270), ERα(180–595), ERα(300–595), ERα(180–353), ERαΔ185–240, ERαΔ240–311, ERαΔ240–270, ERαΔ270–311, or ERβ was incubated with 40 μl of TnT Quick Master Mix and 20 μCi of [35S]methionine (PerkinElmer Life Sciences) for 90 min at 30 °C. TnT products were diluted in Buffer A and used in pulldown assays.

Generation of Cell Lines with Stable IQGAP1 Knockdown

To obtain a control plasmid for knockdown experiments, siRNA sequences of Renilla luciferase, 5-AAACAUGCAGAAAAUGCUG-3 (sense) and 5-CAGCAUUUUCUGCAUGUUU-3 (antisense), were inserted into the pRETRO-SUPER vector (OligoEngine) and named pRETRO-SUPER-siRenilla. To generate retroviruses, HEK293 cells were co-transfected with pUVMC, pCMV-VSV-G (Addgene plasmids 8454 and 8449, respectively, deposited by Robert Weinberg) (24) and either pRETRO-SUPER-siRenilla or pRETRO-SUPER-siIQ8 (25). After 48 h, the medium from the HEK293 cells was harvested for active retroviruses. MCF-7 cell lines were infected with retrovirus essentially as described previously (25). To produce MCF-siIQ15, IQGAP1 siRNA (human) lentiviral particles (Santa Cruz Biotechnology, sc-35700) were used. This siRNA is a pool of three different siRNA duplexes as 5-CCACAGUGAUCUUGCUGAA-3 (sense), 5-UUCAGCAAGAUCACUGUGGtt-3 (antisense) (sc-35700A), 5-GGAUGAAUUUCCUGAAGAA-3 (sense), 5-UUCUUCAGGAAAUUCAUCCtt-3 (antisense) (sc-35700B), 5-CCACAAAGAUGAAGUUGUA-3 (sense), and 5-UACAACUUCAUCUUUGUGG-3 (antisense) (sc-35700C). MCF-7 cells were infected with the siRNA pool according to the manufacturer's instructions. Puromycin (Invitrogen) selection was used to obtain MCF-7 cells stably expressing the different siRNAs. The MCF-7 cell lines infected with pRETRO-SUPER-IQ8 and with siRNA lentiviral particles (sc-35700) are named MCF-siIQ8 (25) and MCF-siIQ15, respectively. The expression levels of IQGAP1 were assessed by Western blotting.

Immunoprecipitation

HEK293 cells were plated in 10-cm dishes to obtain 80% confluence. After 24 h, each plate was transfected with 5 μg of myc-tagged IQGAP1 and either 5 μg of myc-tagged ERα or FLAG-tagged ERβ plasmids. The following day, cells were washed with ice-cold PBS and lysed with 500 μl of Buffer B. Lysates were subjected to sonication for 10 s, and insoluble material was precipitated by centrifugation at 20,000 × g for 10 min at 4 °C. Supernatants were precleared with glutathione-Sepharose beads for 1 h. Equal amounts of protein lysate were incubated with protein A-Sepharose beads and either rabbit IgG, anti-IQGAP1 polyclonal antibodies, anti-ERα polyclonal antibodies, or anti-FLAG affinity gel for 3 h at 4 °C. Samples were washed five times with Buffer A, resolved by SDS-PAGE, and processed by Western blotting.

Paraformaldehyde cross-linking was performed using a modification of a procedure described previously (26). MCF-7 and T47D cells were grown to 90% confluence and incubated in 1 ml of 0.2% paraformaldehyde in PBS for 10 or 20 min at 22 °C. The cross-linking reaction was terminated by adding 1.25 m glycine to a final concentration of 125 mm. After 5 min, cells were washed with PBS and lysed with Buffer B. Cell lysates were processed by immunoprecipitation with rabbit IgG or anti-ERα polyclonal antibodies using the protocol described above.

E2 Stimulation

HEK293 cells were cultured in phenol red-free medium with 10% charcoal-stripped FBS. After 24 h, cells were transfected with both IQGAP1 and ERα plasmids as described above. The following day, the medium was replaced with fresh medium containing 100 nm E2 or vehicle (ethanol). After 15 min, 30 min, 60 min, 120 min or 360 min, E2 stimulation was stopped by washing cells with PBS and lysing them with Buffer B. Immunoprecipitation with anti-IQGAP1 polyclonal antibodies and Western blotting were performed as described above.

Quantitative RT-PCR

To measure pS2 hnRNA, MCF-7 cells were incubated in phenol red-free medium for 24 h. Then vehicle (EtOH) or E2 (to obtain a final concentration of 100 nm) was added to the medium. After 6 h, cells were harvested, and total RNA was isolated from the cells using TRIzol (Invitrogen). 1 μg of RNA was reverse transcribed to cDNA using a High Capacity cDNA Reverse Transcriptase kit (Applied Biosystems) according to the manufacturer's instructions. RT-PCR was performed on a StepOnePlus Real Time PCR system (Applied Biosystems) using SYBR Green PCR Master Mix (Applied Biosystems) and 200 nm forward and reverse primers. The primers used were: pS2 hnRNA, forward primer, 5-TTGGAGAAGGAAGCTGGATGG-3 (start position 3997, within the intron); reverse primer, 5-ACCACAATTCTGTCTTTCACGG-3 (start position 4126, within the second exon); and β-actin, forward primer, 5-TGCGTGACATTAAGGAGAAG-3; reverse primer, 5-GCTCGTAGCTCTTCTCCA-3. RT-PCR enzyme activation was initiated for 10 min at 95 °C and then amplified by 40 cycles (15 s at 95 °C and 1 min at 60 °C). All samples were assayed in triplicate, and β-actin was used as an internal control. Results were analyzed using the ΔΔCT method with StepOnePlus software (Applied Biosystems).

Measurement of PR and cyclin D1 hnRNA was performed as described for pS2 with the following modifications. MCF-7 cells were incubated in phenol red-free medium for 72 h. Vehicle (EtOH) or E2 (final concentration of 10 nm) was added to the medium for 4 h after which cells were harvested and processed as described in the preceding paragraph. The primers used were: cyclin D1, forward primer, 5-GGATGCTGGAGGTCTGCGA-3; reverse primer, 5-AGAGGCCACGAACATGCAAG-3; PR, forward primer, 5-CCTCGGACACCTTGCCTGAA-3; reverse primer, 5-CGCCAACAGAGTGTCCAAGAC-3.

Cell Proliferation Assays

Cell proliferation was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye method performed essentially as previously described (27). Briefly, MCF-siIQ8, MCF-siIQ15, and MCF-7 cells expressing control siRNA were plated in 96-well, flat bottom tissue culture plates. After incubating for 24 h at 37 °C in 5% CO2, the medium was changed to phenol red-free DMEM. E2 (final concentration of 50 nm) or an equal volume of EtOH (vehicle) was added, and cells were incubated for another 72 h. Then 15 μl of Dye Solution (Promega 2015-09-14) was added, and the cells were incubated for 4 h. 100 μl of Solubilization/Stop Solution (Promega 2016-04-21) was added to each well, and the absorbances were determined at 570 nm using a SYNERGY4 multilabel counter (BioTek). The reference wavelength was 700 nm. All of the assays were performed in triplicate.

Miscellaneous Methods

Statistical analysis was performed by Student's t test with Prism 6 (GraphPad). Western blot images were quantified with Image Studio 2.0 (LI-COR Biosciences) according to the manufacturer's instructions. Protein concentrations were determined with the DC Protein Assay (Bio-Rad).

RESULTS

IQGAP1 and ERα Bind Directly in Vitro

Analysis was performed in vitro with pure proteins to ascertain whether IQGAP1 and ERα interact. Pure ERα was incubated with a GST fusion protein of full-length IQGAP1, and complexes were isolated with glutathione-Sepharose beads. Western blotting showed that ERα bound to IQGAP1 (Fig. 1A). By contrast, no ERα binding was detected to GST alone, validating the specificity of the association with IQGAP1. The interaction was confirmed by pulldown with GST-ERα. IQGAP1 was cleaved from GST, and the purified protein was incubated with a GST fusion protein of full-length ERα. Complexes were isolated, and Western blotting was performed. IQGAP1 bound GST-ERα (Fig. 1B). No IQGAP1 was detected with GST alone. Coomassie staining showed the expression of GST-tagged IQGAP1 and ERα proteins (Fig. 1).

FIGURE 1.

FIGURE 1.

IQGAP1 and ERα bind directly in vitro. A, 1 μg of GST-IQGAP1 (IQGAP1) or 1 μg of GST alone bound to glutathione-Sepharose was incubated with 1 μg of pure ERα. Complexes were isolated and washed as described under “Experimental Procedures.” The samples were separated by SDS-PAGE, and the gel was cut at the 100-kDa. The lower portion of the gel was transferred to PVDF, and the blot was probed with anti-ERα monoclonal antibody (WB; top panel). The upper part of the gel was stained with Coomassie Blue (Coomassie; lower panel). Input is pure ERα. B, 4 μg of GST-ERα (ERα) or 4 μg of GST alone bound to glutathione-Sepharose was incubated with 1 μg of purified IQGAP1. Complexes were isolated and washed as described under “Experimental Procedures.” The samples were separated by SDS-PAGE, and the gel was cut at the 100-kDa region. The top part of the gel was transferred to PVDF, and the blot was probed with anti-IQGAP1 polyclonal antibodies (WB; top panel). The bottom part of the gel was stained with Coomassie Blue (Coomassie; lower panel). Input is pure IQGAP1. Data are representative of five independent experiments. WB, Western blot.

ERα and IQGAP1 Interact in Cells

To determine whether IQGAP1 and ERα interact in a normal cell milieu, we used cultured human breast epithelial cell lines that express ERα. MCF-7 cells were lysed and incubated with GST-IQGAP1. Endogenous ERα bound to GST-IQGAP1 (Fig. 2A, left panel). The specificity of binding was confirmed by the absence of ERα from the samples incubated with GST alone. Essentially identical results were obtained with a second ERα-containing human breast epithelial cell line, T47D (Fig. 2A, right panel).

FIGURE 2.

FIGURE 2.

ERα and IQGAP1 interact in cells. A, 4 μg of GST-IQGAP1 (IQGAP1) or 4 μg of GST alone bound to glutathione-Sepharose was incubated with lysates from MCF-7 (left panel) or T47D (right panel) breast epithelial cells. Complexes were isolated and washed as described under “Experimental Procedures.” The samples were separated by SDS-PAGE, and the gel was cut at 100 kDa region. The lower portion of the gel was transferred to PVDF, and the blot was probed with anti-ERα monoclonal antibody (WB; upper panels). The upper part of the gel was stained with Coomassie Blue (lower panels). Aliquots of lysates not subjected to GST pulldown were processed in parallel (Lysate). B, 4 μg of GST-ERα (ERα) or 4 μg of GST alone bound to glutathione-Sepharose was incubated with lysates from MCF-7 (left panel) or T47D (right panel) breast epithelial cells. Complexes were isolated and washed as described under “Experimental Procedures.” The samples were separated by SDS-PAGE, and the gel was cut at the 100-kDa region. The top part of the gel was transferred to PVDF membrane, and the blot was probed with anti-IQGAP1 polyclonal antibodies (WB; upper panels). The bottom part of the gel was stained with Coomassie Blue (lower panels). Aliquots of lysates not subjected to GST pulldown were processed in parallel (Lysate). All data are representative of at least three independent experiments. WB, Western blot.

A reciprocal analysis was conducted with GST-ERα to investigate whether endogenous IQGAP1 binds to ERα. MCF-7 and T47D cell lysates were incubated with GST-ERα. Western blotting documented that IQGAP1 in both cell lines bound specifically to GST-ERα (Fig. 2B). Coomassie staining confirmed the expression of the GST-tagged proteins (Fig. 2).

IQGAP1 and ERα Co-immunoprecipitate

The interaction between IQGAP1 and ERα in intact cells was evaluated by immunoprecipitation. HEK293 cells were transiently co-transfected with ERα and IQGAP1. Immunoprecipitation with anti-ERα antibodies revealed that IQGAP1 binds to ERα in cells (Fig. 3A). No IQGAP1 was detected in the samples precipitated with rabbit IgG, validating the specificity of the interaction. Western blotting confirmed that HEK293 cells did not express ERα, and neither ERα nor IQGAP1 was detected in anti-ERα immunoprecipitates from cells transfected with vector only (Fig. 3A). The transfection was repeated, and lysates were immunoprecipitated with anti-IQGAP1 antibody. ERα co-immunoprecipitated with IQGAP1 (Fig. 3B). No ERα was detected in samples precipitated with IgG or from the cells immunoprecipitated with anti-IQGAP1 antibody but not transfected with ERα. These data confirm the specificity of the interaction.

FIGURE 3.

FIGURE 3.

ERα and IQGAP1 co-immunoprecipitate from cell lysates. A, HEK293 cells were transiently transfected with both IQGAP1 and ERα plasmids or with empty vector alone. After lysis, equal amounts of protein were loaded directly onto the gel (Lysates) or immunoprecipitated (IP) with either anti-ERα polyclonal antibodies (ERα) or rabbit IgG as a negative control. Immune complexes were isolated with protein A-Sepharose. Samples were separated by SDS-PAGE and transferred to PVDF membrane. After blocking, the blot was probed with anti-IQGAP1 polyclonal and anti-ERα monoclonal antibodies. E, empty lane. B, HEK293 cells were transiently transfected as described for A. Equal amounts of protein lysate were immunoprecipitated (IP) with either anti-IQGAP1 polyclonal antibodies (IQ) or rabbit IgG as a negative control. Samples were processed by Western blotting. E, empty lane. All data in A and B are representative of at least three independent experimental determinations. C, untransfected MCF-7 (left panel) and T47D (right panel) cells were incubated with 0.2% paraformaldehyde and processed as described under “Experimental Procedures.” Equal amounts of cell lysates were immunoprecipitated with anti-ERα antibody. Rabbit IgG was used as a negative control. Samples were processed by Western blotting for IQGAP1 and ERα. An aliquot of lysate was processed in parallel. All data are representative of six (for MCF-7 cells) or three (for T47D cells) independent experiments.

We used both MCF-7 and T47D cells to examine whether endogenous IQGAP1 binds to endogenous ERα. Cells were exposed to a cross-linker, paraformaldehyde, before lysis. Formaldehyde, which has short spacer arms, is widely used to stabilize protein-protein interactions. Immunoprecipitation with anti-ERα antibody revealed that IQGAP1 co-immunoprecipitated with ERα from MCF-7 (Fig. 3C, left panel) and T47D cells (Fig. 3C, right panel). Very little protein was seen in samples precipitated with IgG, indicating that endogenous ERα binds to endogenous IQGAP1 in both MCF-7 and T47D cells.

ERα Binds to the IQ Region of IQGAP1

To determine the region of IQGAP1 to which ERα binds, selected portions of IQGAP1 (Fig. 4A) were labeled with [35S]methionine in a reticulocyte lysate. The constructs were incubated with GST-ERα and isolated with glutathione-Sepharose beads. After washing, samples were resolved by SDS-PAGE, transferred to PVDF, and processed by autoradiography. As shown with both pure proteins and cell lysates (Figs. 1B and 2B), full-length IQGAP1 expressed with the TnT system bound to GST-ERα (Fig. 4B, top panel). Analysis with smaller fragments revealed that the N-terminal half of IQGAP1 interacted with GST-ERα, but the C-terminal half of IQGAP1 did not bind. Specificity of binding to GST-ERα was confirmed by the absence of bands from the samples incubated with GST alone (Fig. 4B, middle panel). The level of expression of each TnT product was approximately equivalent (Fig. 4B, bottom panel).

FIGURE 4.

FIGURE 4.

ERα binds to the IQ region of IQGAP1. A, schematic representation of IQGAP1 constructs. Full-length IQGAP1 and deletion mutants are depicted. The specific amino acid residues in each construct are indicated. CHD, calponin homology domain; WW, polyproline-binding domain; IQ, IQ domain containing four IQ motifs; GRD, Ras GTPase-activating protein-related domain; RGCT, Ras GTPase-activating protein C terminus. FL, full-length IQGAP1; N, N-terminal half of IQGAP1; C, C-terminal half of IQGAP1; IQ, IQ region of IQGAP1; ΔIQ, full-length IQGAP1 that lacks the IQ region (amino acids 764–863). IQGAP1 construct binding to ERα is shown with binding status defined as follows: +, binding detected; −, no binding. B, [35S]methionine-labeled full-length IQGAP1 (FL), IQGAP1-N (N), IQGAP1-IQ (IQ), IQGAP1-C (C), or IQGAP1ΔIQ (ΔIQ) was incubated with equal amounts of GST-ERα (top panel). Each IQGAP1 construct was also incubated with GST alone (middle panel). Complexes were isolated with glutathione-Sepharose beads and washed. Samples were resolved by SDS-PAGE and transferred to PVDF, and blots were processed by autoradiography. In addition, an aliquot of each [35S]methionine-labeled TnT product (equivalent to 5% of the amount that was used in the pulldown) was resolved by SDS-PAGE, transferred to PVDF, and processed by autoradiography (Input; bottom panel). The data are representative of three independent experiments.

Several proteins associate with the IQ region of IQGAP1 (13, 14). To ascertain whether ERα binds to the IQ region, a fragment comprising amino acids 717–916 of IQGAP1 was labeled with [35S]methionine and incubated with GST-ERα. Autoradiography demonstrated that the IQ region of IQGAP1 bound to ERα (Fig. 4B, top panel). Consistent with these findings, deletion of the IQ domain (the construct is termed IQGAP1ΔIQ) abrogated the binding of IQGAP1 to ERα (Fig. 4B, top panel). These data reveal that the IQ region of IQGAP1 is necessary and sufficient for ERα binding.

IQGAP1 Binds to the Hinge Region of ERα

The TnT system was also used to identify the region of ERα with which IQGAP1 interacts. [35S]Methionine-labeled full-length ERα and a series of ERα fragments and deletion mutants (Fig. 5A) were incubated with GST-IQGAP1. The complexes were isolated with glutathione-Sepharose beads and processed by SDS-PAGE and autoradiography. As observed with pure proteins and cell lysates (Figs. 1 and 2), full-length ERα expressed by the TnT system bound to GST-IQGAP1 (Fig. 5B, top panel). Although the N-terminal portion of ERα bound to IQGAP1, the C-terminal portion (ERα(300–595)) did not bind. Extending the C-terminal portion proximally by adding the hinge region and DBD (ERα(180–595)) restored binding equivalent to that of full-length ERα (Fig. 5B, top panel). Similarly, ERα(180–353), which comprises the DBD, hinge, and the proximal portion of the C-terminal of ERα, bound IQGAP1 to essentially the same extent as full-length ERα. Input data reveal that the amounts of each ERα fragment were essentially the same (Fig. 5B, bottom panel).

FIGURE 5.

FIGURE 5.

IQGAP1 binds to the hinge region of ERα. A, schematic representation of ERα constructs. Full-length ERα (FL), truncated ERα fragments, and deletion mutants are depicted. Amino acid residues of each truncated fragment and the specific amino acids absent from each deletion construct (designated with Δ) are indicated. AF-1, activation function-1 (or region A/B); Hinge, hinge region (or region D); HBD/AF-2, hormone-binding domain/activation function-2 (or region E/F). Binding to IQGAP1 is defined as follows: +, binding; wk, weak binding; −, no binding. B, [35S]methionine-labeled full-length ERα (FL), ERα(1–270), ERα(180–595), ERα(300–595), and ERα(180–353) were incubated with equal amounts of GST-IQGAP1 (top panel). Each ERα construct was also incubated with GST alone (middle panel). Complexes were isolated with glutathione-Sepharose beads and washed. Samples were resolved by SDS-PAGE and transferred to PVDF, and blots were processed by autoradiography. In addition, an aliquot of each [35S]methionine-labeled product (equivalent to 5% of the amount that was used for the pulldown) was processed by electrophoresis and blotting as described above (Input; bottom panel). The data are representative of three independent experiments. C, [35S]methionine-labeled full-length ERα (FL), ERαΔ185–240, ERαΔ270–311, ERαΔ240–270, and ERαΔ240–311 were incubated with equal amounts of GST-IQGAP1 (top panel). Each ERα construct was also incubated with GST alone (middle panel). Complexes were isolated, and samples were processed as described for B. An aliquot of each [35S]methionine-labeled product was processed as described above (Input; bottom panel). The data are representative of two independent experiments.

To further narrow the binding region, we deleted selected portions of ERα from the DBD and hinge regions. Analysis of the deletion constructs revealed that removing amino acids 185–240 did not impair binding to IQGAP1 (Fig. 5C). By contrast, ERα constructs that lacked portions of the hinge region (namely ERαΔ240–270 and ERαΔ270–311) exhibited weak binding, and removal of amino acids 240–311 abrogated binding. Collectively, these data strongly suggest that IQGAP1 binds to ERα between amino acids 240 and 311, and the whole hinge region of ERα is needed for effective binding.

E2 Attenuates the Binding between IQGAP1 and ERα

The possible effect of E2 on the interaction between IQGAP1 and ERα was investigated. HEK293 cells transiently transfected with IQGAP1 and ERα were stimulated with E2 for different time intervals, and the association between the two proteins was examined by co-immunoprecipitation. Consistent with prior reports (10), we observed a decrease in the total ERα in lysates of cells treated with E2 that became statistically significant at 360 min (Fig. 6, A and B). As anticipated, E2 did not significantly change the amount of IQGAP1 in the lysates or in the immunoprecipitates. By contrast, the amount of ERα that co-immunoprecipitated with IQGAP1 decreased in a time-dependent manner (Fig. 6, A and C). To correct for the reduction of total ERα produced by E2, we quantified both the total amount of ERα in the cells and the amount of ERα in anti-IQGAP1 immunoprecipitates. After correction for total ERα in lysates, the amount of ERα that co-immunoprecipitated with IQGAP1 from E2-stimulated cells was lower than that from control cells (Fig. 6D). Reduction was seen at the earliest time point (15 min) and became statistically significant at 60 min, and at 360 min of E2 treatment, the amount of ERα that co-immunoprecipitated with IQGAP1 was reduced by 58 ± 6.5% (mean ± S.E., n = 3). These data reveal that E2 modulates the interaction between IQGAP1 and ERα in cells.

FIGURE 6.

FIGURE 6.

E2 attenuates the binding between IQGAP1 and ERα. A, HEK293 cells were grown in phenol red-free DMEM with 10% charcoal-stripped FBS and transiently transfected with both IQGAP1 and ERα (lanes 1–7) or with empty vector alone (lane 8). 24 h after the transfection, cells were incubated with 100 nm E2 for 0, 15, 30, 60, 120, or 360 min. After lysis, equal amounts of protein lysate were immunoprecipitated (IP) with either anti-IQGAP1 polyclonal antibodies (lanes 1–6 and 8) or rabbit IgG (lane 7). Immunoprecipitates and aliquots of lysates were resolved by SDS-PAGE, transferred to PVDF, and probed with anti-IQGAP1 and anti-ERα antibodies. The data are representative of three independent experiments. B, C, and D, the ERα bands in the blots were quantified with Image Studio 2.0 (LI-COR Biosciences). B, total amount of ERα in the lysate (Lysate). C, total amount of ERα co-immunoprecipitated (IP) with IQGAP1. D, co-immunoprecipitated ERα was corrected for the total amount of ERα in the corresponding lysate (IP/Lysate). Data are expressed as means ± S.E. (error bars) (n = 3) with 0 min set as 1. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Knockdown of IQGAP1 Impairs ERα Function

We evaluated the possible role of IQGAP1 in ERα function. ERα-positive MCF-7 cell lines were chosen because they express high levels of IQGAP1 (25, 27). We used two different MCF-7 cell lines with stable IQGAP1 knockdown by siRNA. These cells, termed MCF-siIQ8 and MCF-siIQ15, had IQGAP1 protein levels 65 ± 8 and 66 ± 4% (mean ± S.E., n = 4), respectively, lower than control cells (Fig. 7A, left panel, and B). E2-induced transcriptional activation of pS2 was measured. E2 produced a 7.2 ± 0.6-fold (mean ± S.E., n = 3) increase in pS2 hnRNA in MCF-7 cells stably expressing control siRNA (Fig. 7C). The ability of E2 to stimulate pS2 hnRNA was significantly attenuated when the amount of IQGAP1 was reduced. E2 stimulated pS2 hnRNA expression in MCF-siIQ8 and MCF-siIQ15 cells by only 2.7 ± 0.2- and 3.8 ± 0.5-fold (mean ± S.E.), respectively (Fig. 7C). Note that knockdown of IQGAP1 did not significantly reduce the amount of ERα in the MCF-7 cell lines (Fig. 7A). Moreover, the level of the ERα in cells incubated with E2 was not significantly altered by IQGAP1 knockdown (Fig. 7A, right panel). E2 stimulation reduced the amount of ERα as observed in Fig. 6A and described previously (10). Collectively, these data validate that IQGAP1 is required for maximal E2-stimulated transcriptional activation of pS2 in MCF-7 cells.

FIGURE 7.

FIGURE 7.

Knockdown of IQGAP1 alters ERα function. A, MCF-7 cells were stably transfected with siRNA against Renilla luciferase (Control) or two distinct siRNAs directed against different regions of IQGAP1 (siIQ8 and siIQ15). Where indicated, cells were cultured in phenol red-free medium for 24 h followed by incubation with vehicle (EtOH) or 100 nm E2 for 6 h (right panel). Cells were lysed, and equal amounts of protein lysate were analyzed by Western blotting. B, the amount of IQGAP1 in the Western blot was quantified with Image Studio 2.0 (LI-COR Biosciences) and corrected for the amount of actin in the corresponding sample. Data represent the means ± S.E. (error bars) of three independent experiments with control cells set as 1. ***, p < 0.001. C, MCF-7 cells stably expressing control siRNA, siIQ8, or siIQ15 were incubated in phenol red-free medium for 24 h followed by 6-h incubation with vehicle (EtOH; black bars) or 100 nm E2 (white bars). Total RNA was extracted, and quantitative RT-PCR analysis was performed to measure pS2 hnRNA. The amount of hnRNA in each sample was corrected for β-actin hnRNA in the same sample. Vehicle-treated cells were set as 1. The data represent the means ± S.E. (error bars) of three independent experiments, each performed in triplicate. *, p < 0.05; **, p < 0.01 compared with the control cell line treated with E2. D, MCF-7 cells expressing control siRNA, siIQ8, or siIQ15 were incubated in phenol red-free medium with vehicle (EtOH; black bars) or 10 nm E2 (white bars) for 4 h. Quantitative RT-PCR analysis was performed to measure PR hnRNA, and samples were analyzed as described for pS2. The data represent the means ± S.E. (error bars) of three independent experiments for control and siIQ8 cells and two independent experiments for siIQ15 cells. *, p < 0.05 compared with the control cell line treated with E2. E, control and sIQ8 cell lines were incubated in phenol red-free medium with vehicle (EtOH; black bars) or 10 nm E2 (white bars) for 4 h, and cyclin D1 hnRNA was measured by quantitative RT-PCR. Samples were analyzed as described for pS2. A representative experiment of three independent determinations is shown. F, cell proliferation was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as described under “Experimental Procedures.” Data are representative of three independent experimental determinations, each performed in triplicate.

To extend these findings, we examined the effects of IQGAP1 on the ability of ERα to activate two other endogenous estrogen-responsive genes, namely PR and cyclin D1. Analysis revealed that E2 stimulation of PR hnRNA was significantly impaired in both MCF-siIQ8 and MCF-siIQ15 cells (Fig. 7D). Similarly, reducing the amount of IQGAP1 in MCF-7 human breast epithelial cells decreased stimulation of cyclin D1 hnRNA by E2 (Fig. 7E). These results support our observations with pS2 and confirm that endogenous IQGAP1 contributes to normal transcriptional function of ERα.

In addition to promoting transcription of selected genes, ERα mediates an increase in cell proliferation (1). We evaluated the possible role of IQGAP1 in this process. The ability of E2 to enhance proliferation of MCF-7 control cells was compared with cells with IQGAP1 knockdown, namely MCF-siIQ8 and MCF-siIQ15 cells. Reducing IQGAP1 levels in MCF-7 cells abrogated the stimulation of cell proliferation by E2 (Fig. 7F).

ERβ Binds to IQGAP1

We investigated the possible interaction between IQGAP1 and ERβ, which is another member of the ER family with a domain structure similar to that of ERα (Fig. 8A). Pure ERβ was incubated with a GST fusion protein of full-length IQGAP1, and complexes were isolated with glutathione-Sepharose beads. Western blotting showed that ERβ bound to IQGAP1 (Fig. 8B). By contrast, no ERβ binding was detected to GST alone, validating the specificity of the association with IQGAP1. Coomassie staining showed GST-IQGAP1 and GST (Fig. 8B). ERβ, synthesized with TnT and labeled with [35S]methionine, bound specifically to GST-IQGAP1 (Fig. 8C). Thus, IQGAP1 and ERβ interact directly.

FIGURE 8.

FIGURE 8.

ERβ binds to IQGAP1 in vitro. A, schematic representation of ERα and ERβ. AF-1, activation function-1; Hinge, hinge region; HBD/AF-2, hormone-binding domain/activation function-2. The homology between the domains of the proteins is depicted below. The figure is adapted from Thomas and Gustafsson (1). B, 4 μg of GST-IQGAP1 (IQGAP1) or 4 μg of GST alone bound to glutathione-Sepharose was incubated with 1 μg of pure ERβ. Complexes were isolated and washed as described under “Experimental Procedures.” The samples were separated by SDS-PAGE, and the gel was cut at both the 100- and 37-kDa regions. The portion of the gel between 37 and 100 kDa was transferred to PVDF, and the blot was probed with anti-ERβ monoclonal antibody (WB; top panel). The top and bottom parts of the gel containing GST-IQGAP1 and GST, respectively, were stained with Coomassie Blue. Input is pure ERβ. C, [35S]methionine-labeled ERβ was incubated with 4 μg of GST-IQGAP1 or GST alone. Complexes were isolated with glutathione-Sepharose beads and washed. Samples were resolved by SDS-PAGE and transferred to PVDF, and blots were processed by autoradiography. In addition, the [35S]methionine-labeled product (equivalent to 5% of the amount that was used for the pulldown) was processed as described above (Input). Data are representative of at least two independent experiments. WB, Western blot.

Immunoprecipitation was performed to ascertain whether IQGAP1 and ERβ associate in cells. HEK293 cells were transiently transfected with IQGAP1 and FLAG-tagged ERβ. Immunoprecipitation with anti-FLAG antibodies revealed that IQGAP1 bound to ERβ in cells (Fig. 9A). Analogous experiments were performed in which cells were transfected and lysates were immunoprecipitated with anti-IQGAP1 antibodies. ERβ co-immunoprecipitated with IQGAP1 (Fig. 9B). Neither IQGAP1 nor ERβ was seen in samples precipitated with IgG nor was ERβ seen in samples obtained from cells transfected with empty vector (Fig. 9, A and B). The blots were also probed with anti-ERβ antibodies, which confirmed that the bands detected with anti-FLAG antibodies are ERβ (data not shown). Collectively, these data reveal that ERβ and IQGAP1 interact in cells.

FIGURE 9.

FIGURE 9.

ERβ and IQGAP1 co-immunoprecipitate from cell lysates. A, HEK293 cells were transiently transfected with both IQGAP1 and FLAG-tagged ERβ plasmids or with empty vector alone. After lysis, equal amounts of protein were loaded directly onto the gel (Lysates) or immunoprecipitated (IP) with either anti-FLAG affinity gel (Flag) or IgG (negative control). Samples were separated by SDS-PAGE and transferred to PVDF membrane. After blocking, the blot was probed with anti-IQGAP1 polyclonal (top panel) and anti-FLAG monoclonal antibodies (bottom panel). E, empty lane. B, HEK293 cells were transiently transfected as described for A. Equal amounts of protein lysate were immunoprecipitated (IP) with either anti-IQGAP1 polyclonal antibodies (IQ) or rabbit IgG (negative control). Aliquots of lysates not subjected to immunoprecipitation were processed in parallel (Lysates). Samples were processed by Western blotting and probed with anti-IQGAP1 polyclonal (top panel) and anti-FLAG monoclonal antibodies (bottom panel). E, empty lane. Data are representative of two independent experiments.

DISCUSSION

IQGAP1 interacts with numerous proteins, thereby coordinating the assembly of multiprotein complexes and modulating diverse signaling pathways (13). For example, IQGAP1 binds to several components of the epidermal growth factor receptor-Raf-MAPK cascade, regulating activation of ERK (13, 17, 28). Work from a number of groups has demonstrated that IQGAP1 associates with selected transmembrane receptors and participates in their normal function (13, 14). Here we show for the first time that IQGAP1 also interacts directly with nuclear receptors. We demonstrate that IQGAP1 binds to both ERα and ERβ and influences ERα transcriptional function.

Based on the presence of three LXXLL motifs located at amino acid residues 347–351, 975–979, and 1646–1650 in IQGAP1, we predicted that ERα would bind one or more of these regions. The data did not validate this hypothesis. ERα did not associate with the C-terminal half of IQGAP1, which contains two of the LXXLL regions. Although ERα bound the N-terminal half of IQGAP1, which contains the other LXXLL motif, amino acids 717–916 of IQGAP1 were sufficient for binding ERα, indicating that the LXXLL motif at amino acids 347–351 does not mediate binding. Moreover, the observation that deletion of amino acids 763–864 from IQGAP1 eliminated its association with ERα confirms that the IQ region of IQGAP1 is the site to which ERα binds. Several other proteins, including calmodulin (29, 30), myosin light chain (31), Rap1 (32), human epidermal growth factor receptor-2 (16), epidermal growth factor receptor (17), and S100B (33), also bind to the IQ region of IQGAP1. Protein binding to IQGAP1 may be regulated. For example, Ca2+ modulates the interaction of calmodulin with the IQ region of IQGAP1 (21, 29). Similarly, Zn2+ promotes the association of S100B with the IQ motif of IQGAP1 (33). In addition, although there are no published data, it is likely that the different proteins bind the IQ domains of IQGAP1 with different affinities. Therefore, a cell may have several distinct IQGAP1 complexes with different proteins associated with the IQ region depending on signaling inputs, subcellular location, cell type, and other factors.

An important finding in our study is that E2 regulated the association between IQGAP1 and ERα. The effects of ligand binding on the interaction of receptors with IQGAP1 are diverse. For example, EGF has no effect on the association between IQGAP1 and epidermal growth factor receptor (17). By contrast, stimulation of Madin-Darby bovine kidney cells with FGF2 promotes binding of fibroblast growth factor receptor 1 to IQGAP1 (18). Similarly, VEGF enhances the interaction of vascular endothelial growth factor receptor-2 with IQGAP1 in human umbilical vein endothelial cells (19), and transforming growth factor β-1 (TGF-β1) increases the binding of IQGAP1 to TGF-β receptor II (34). In contrast to these data, we observed that E2 significantly attenuated the interaction between IQGAP1 and ERα in cells. To our knowledge, this is the first description of a ligand that reduces receptor binding to IQGAP1.

Prior publications have identified the participation of IQGAP1 in transcriptional activation. β-Catenin is an integral component of the cadherin cell adhesion complex, and it co-activates transcription factors in the nucleus (35). IQGAP1 binds β-catenin and regulates its function (36, 37). Overexpression of IQGAP1 significantly enhances β-catenin-mediated transcriptional co-activation in SW480 colon carcinoma cells (37). Although IQGAP1 was not detected in the nucleus, IQGAP1 overexpression increased the amount of β-catenin in the nucleus. Similarly, IQGAP1 regulates the nuclear translocation of nuclear factor of activated T cells (NFAT) and alters transcription of NFAT target genes (38). More recent studies have revealed that IQGAP1 regulates nuclear translocation and transcriptional activation of both nuclear factor-erythroid-related factor 2 (Nrf2) (39) and Dishevelled (40). Analogous to our observations with ERα transcriptional activation, knockdown of IQGAP1 impairs the transcriptional activation of target genes by Nrf2 and Dishevelled (39, 40). By contrast, CD8+ T cells isolated from IQGAP1-deficient mice exhibit increased expression of interferon-γ, an established target gene of NFAT (38). Thus, IQGAP1 exerts different effects on different gene transcription pathways.

For ERα, IQGAP1 is necessary for E2 to maximally stimulate transcription of the pS2, PR, and cyclin D1 genes. Knockdown of IQGAP1 by two distinct siRNAs directed against different regions of IQGAP1 significantly reduced the ability of E2 to stimulate transcription of pS2 and PR. This finding initially appears to contradict the observation that E2 attenuated the interaction between IQGAP1 and ERα in cells. The knockdown experiments imply that IQGAP1 is required for ERα to enhance pS2 transcription, whereas the co-immunoprecipitation experiments revealed that E2 reduced the interaction of ERα with IQGAP1 at the same time point (6 h) at which pS2 transcription was analyzed. Taken together, these data suggest that a direct interaction with IQGAP1 in the nucleus is not required for ERα to promote pS2 gene transcription. Although IQGAP1 has been reported in the nucleus, the pool is small (≈5% of total IQGAP1) (41). Moreover, IQGAP1 accumulates in the nucleus at the G1/S phase of the cell cycle and appears to contribute to cell cycle progression. Although not impossible, it is unlikely that nuclear IQGAP1 makes a substantial contribution to ERα function. There are several possible ways in which IQGAP1 may modulate ERα function. 1) The binding may alter ERα degradation by the ubiquitin-proteasome system. The transcriptional activity of ERα is linked to receptor turnover. Inhibition of ERα degradation leads to its stabilization but also to loss of its transcriptional activity (42). However, there is no evidence that IQGAP1 alters ERα degradation as we observed that reducing the intracellular amount of IQGAP1 in MCF-7 cells did not significantly change the amount of ERα. Therefore, changing ERα degradation is probably not the mechanism by which IQGAP1 influences ERα transcription. 2) Numerous cofactors associate with ERα in interconnected networks of proteins (9). IQGAP1 is a scaffold that integrates signaling pathways and may coordinate the assembly of a multiprotein complex to regulate ERα function. 3) IQGAP1 may alter the ability of ERα to bind other proteins. IQGAP1 binds to the hinge (D) region of ERα. Initially believed to serve exclusively as a flexible linker between the DBD and ligand-binding domain, evidence accumulated over the last decade has identified important functional roles for the hinge region of ERα. For example, a recent study reveals that selective mutations in the D domain of ERα alter its nuclear translocation and its ability to activate its target genes activator protein-1, pS2, and specific protein-1 (43). One of the mutant ERα constructs generated in that study can translocate to the nucleus and bind to DNA in the presence of E2 but is unable to interact with the necessary tethering factors to activate activator protein-1 and specific protein-1 response elements. The hinge region is implicated in interconnections with some co-regulator molecules (42). It is possible that IQGAP1 sterically hinders the interaction of one (or more) co-regulators, thereby changing pS2, PR, and cyclin D1 transcription. 4) In addition, several post-translational modifications, including phosphorylation, acetylation, methylation, and ubiquitination, occur in the hinge region of ERα (44). These covalent additions, which affect receptor activity, could be modified by IQGAP1 binding. 5) A nuclear localization signal is contained in the hinge region, and IQGAP1 could conceivably regulate the nuclear translocation of ERα as it does for β-catenin, NFAT, and Nrf2 (3739). 6) Finally, IQGAP1 is known to dimerize (22). Although the dimerization domain of ERα is outside the hinge region, IQGAP1 could enhance ERα dimerization, analogous to that produced by calmodulin. Detailed structural analysis reveals that binding of calmodulin to the hinge region of ERα promotes dimerization of ERα (45). These possible mechanisms are not mutually exclusive, and more than one may be responsible for the effects we observed with IQGAP1. Additional work is required to dissect these possibilities and elucidate the molecular mechanism(s) by which IQGAP1 regulates ERα transcriptional activation.

Association of IQGAP1 with members of the steroid receptor family is not confined to ERα. We observed a direct in vitro interaction of pure ERβ with pure IQGAP1. Importantly, the two proteins co-immunoprecipitated from cell lysates, revealing that they interact in cells. Further studies are needed to determine whether the interaction with IQGAP1 alters ERβ function. Moreover, several other nuclear receptors, including the androgen receptor, glucocorticoid receptor, progesterone receptor, thyroid receptor, and vitamin D receptor, have domain structures similar to that of ER (46). We are examining the possible interactions of these receptors with IQGAP1, and if binding is detected, we plan to investigate whether IQGAP1 has any effects on receptor function.

Our data identify a previously unrecognized interaction between the nuclear receptor ERα and IQGAP1. Experimental evidence supports the notion that IQGAP1 modulates ERα transcriptional activation of pS2, PR, and cyclin D1. These observations enhance our comprehension of both ERα signaling and IQGAP1 function. Importantly, a large body of data implicates both ERα (47) and IQGAP1 (27, 48) in breast carcinoma. It seems feasible that therapeutic agents directed toward the interaction between ERα and IQGAP1 might be useful in the management of patients with breast carcinoma.

Acknowledgments

We thank Bhavna Chawla and past members of the Sacks laboratory for insightful discussions.

*

This work was supported, in whole or in part, by the National Institutes of Health Intramural Research Program.

3
The abbreviations used are:
ER
estrogen receptor
E2
17β-estradiol
PR
progesterone receptor
hnRNA
heterogenous nuclear RNA
DBD
DNA-binding domain
NFAT
nuclear factor of activated T cells
Nrf2
nuclear factor-erythroid-related factor 2
TnT
transcription and translation.

REFERENCES

  • 1. Thomas C., Gustafsson J. Å. (2011) The different roles of ER subtypes in cancer biology and therapy. Nat. Rev. Cancer 11, 597–608 [DOI] [PubMed] [Google Scholar]
  • 2. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Ström A., Treuter E., Warner M., Gustafsson J. A. (2007) Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87, 905–931 [DOI] [PubMed] [Google Scholar]
  • 3. Levin E. R. (2009) Membrane oestrogen receptor α signalling to cell functions. J. Physiol. 587, 5019–5023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Manavathi B., Dey O., Gajulapalli V. N., Bhatia R. S., Bugide S., Kumar R. (2013) Derailed estrogen signaling and breast cancer: an authentic couple. Endocr. Rev. 34, 1–32 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Philips A., Chalbos D., Rochefort H. (1993) Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J. Biol. Chem. 268, 14103–14108 [PubMed] [Google Scholar]
  • 6. Porter W., Saville B., Hoivik D., Safe S. (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 11, 1569–1580 [DOI] [PubMed] [Google Scholar]
  • 7. Aronica S. M., Katzenellenbogen B. S. (1991) Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3′,5′-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors. Endocrinology 128, 2045–2052 [DOI] [PubMed] [Google Scholar]
  • 8. Brown A. M., Jeltsch J. M., Roberts M., Chambon P. (1984) Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. Natl. Acad. Sci. U.S.A. 81, 6344–6348 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Schultz-Norton J. R., Ziegler Y. S., Nardulli A. M. (2011) ERα-associated protein networks. Trends Endocrinol. Metab. 22, 124–129 [DOI] [PubMed] [Google Scholar]
  • 10. Li Z., Joyal J. L., Sacks D. B. (2001) Calmodulin enhances the stability of the estrogen receptor. J. Biol. Chem. 276, 17354–17360 [DOI] [PubMed] [Google Scholar]
  • 11. Li L., Li Z., Howley P. M., Sacks D. B. (2006) E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 281, 1978–1985 [DOI] [PubMed] [Google Scholar]
  • 12. Li L., Li Z., Sacks D. B. (2005) The transcriptional activity of estrogen receptor-alpha is dependent on Ca2+/calmodulin. J. Biol. Chem. 280, 13097–13104 [DOI] [PubMed] [Google Scholar]
  • 13. Brown M. D., Sacks D. B. (2006) IQGAP1 in cellular signaling: bridging the GAP. Trends Cell Biol. 16, 242–249 [DOI] [PubMed] [Google Scholar]
  • 14. White C. D., Erdemir H. H., Sacks D. B. (2012) IQGAP1 and its binding proteins control diverse biological functions. Cell. Signal. 24, 826–834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Noritake J., Watanabe T., Sato K., Wang S., Kaibuchi K. (2005) IQGAP1: a key regulator of adhesion and migration. J. Cell Sci. 118, 2085–2092 [DOI] [PubMed] [Google Scholar]
  • 16. White C. D., Li Z., Dillon D. A., Sacks D. B. (2011) IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance. J. Biol. Chem. 286, 29734–29747 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. McNulty D. E., Li Z., White C. D., Sacks D. B., Annan R. S. (2011) MAPK scaffold IQGAP1 binds the EGF receptor and modulates its activation. J. Biol. Chem. 286, 15010–15021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Benseñor L. B., Kan H. M., Wang N., Wallrabe H., Davidson L. A., Cai Y., Schafer D. A., Bloom G. S. (2007) IQGAP1 regulates cell motility by linking growth factor signaling to actin assembly. J. Cell Sci. 120, 658–669 [DOI] [PubMed] [Google Scholar]
  • 19. Yamaoka-Tojo M., Ushio-Fukai M., Hilenski L., Dikalov S. I., Chen Y. E., Tojo T., Fukai T., Fujimoto M., Patrushev N. A., Wang N., Kontos C. D., Bloom G. S., Alexander R. W. (2004) IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species-dependent endothelial migration and proliferation. Circ. Res. 95, 276–283 [DOI] [PubMed] [Google Scholar]
  • 20. Heery D. M., Kalkhoven E., Hoare S., Parker M. G. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733–736 [DOI] [PubMed] [Google Scholar]
  • 21. Ho Y. D., Joyal J. L., Li Z., Sacks D. B. (1999) IQGAP1 integrates Ca2+/calmodulin and Cdc42 signaling. J. Biol. Chem. 274, 464–470 [DOI] [PubMed] [Google Scholar]
  • 22. Ren J. G., Li Z., Crimmins D. L., Sacks D. B. (2005) Self-association of IQGAP1: characterization and functional sequelae. J. Biol. Chem. 280, 34548–34557 [DOI] [PubMed] [Google Scholar]
  • 23. Zhang G., Yanamala N., Lathrop K. L., Zhang L., Klein-Seetharaman J., Srinivas H. (2010) Ligand-independent antiapoptotic function of estrogen receptor-β in lung cancer cells. Mol. Endocrinol. 24, 1737–1747 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Stewart S. A., Dykxhoorn D. M., Palliser D., Mizuno H., Yu E. Y., An D. S., Sabatini D. M., Chen I. S., Hahn W. C., Sharp P. A., Weinberg R. A., Novina C. D. (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493–501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Mataraza J. M., Briggs M. W., Li Z., Entwistle A., Ridley A. J., Sacks D. B. (2003) IQGAP1 promotes cell motility and invasion. J. Biol. Chem. 278, 41237–41245 [DOI] [PubMed] [Google Scholar]
  • 26. Vasilescu J., Guo X., Kast J. (2004) Identification of protein-protein interactions using in vivo cross-linking and mass spectrometry. Proteomics 4, 3845–3854 [DOI] [PubMed] [Google Scholar]
  • 27. Jadeski L., Mataraza J. M., Jeong H. W., Li Z., Sacks D. B. (2008) IQGAP1 stimulates proliferation and enhances tumorigenesis of human breast epithelial cells. J. Biol. Chem. 283, 1008–1017 [DOI] [PubMed] [Google Scholar]
  • 28. Ren J. G., Li Z., Sacks D. B. (2007) IQGAP1 modulates activation of B-Raf. Proc. Natl. Acad. Sci. U.S.A. 104, 10465–10469 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Li Z., Sacks D. B. (2003) Elucidation of the interaction of calmodulin with the IQ motifs of IQGAP1. J. Biol. Chem. 278, 4347–4352 [DOI] [PubMed] [Google Scholar]
  • 30. Hart M. J., Callow M. G., Souza B., Polakis P. (1996) IQGAP1, a calmodulin-binding protein with a rasGAP-related domain, is a potential effector for cdc42Hs. EMBO J. 15, 2997–3005 [PMC free article] [PubMed] [Google Scholar]
  • 31. Weissbach L., Bernards A., Herion D. W. (1998) Binding of myosin essential light chain to the cytoskeleton-associated protein IQGAP1. Biochem. Biophys. Res. Commun. 251, 269–276 [DOI] [PubMed] [Google Scholar]
  • 32. Jeong H. W., Li Z., Brown M. D., Sacks D. B. (2007) IQGAP1 binds Rap1 and modulates its activity. J. Biol. Chem. 282, 20752–20762 [DOI] [PubMed] [Google Scholar]
  • 33. Mbele G. O., Deloulme J. C., Gentil B. J., Delphin C., Ferro M., Garin J., Takahashi M., Baudier J. (2002) The zinc- and calcium-binding S100B interacts and co-localizes with IQGAP1 during dynamic rearrangement of cell membranes. J. Biol. Chem. 277, 49998–50007 [DOI] [PubMed] [Google Scholar]
  • 34. Liu C., Billadeau D. D., Abdelhakim H., Leof E., Kaibuchi K., Bernabeu C., Bloom G. S., Yang L., Boardman L., Shah V. H., Kang N. (2013) IQGAP1 suppresses TβRII-mediated myofibroblastic activation and metastatic growth in liver. J. Clin. Investig. 123, 1138–1156 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Clevers H., Nusse R. (2012) Wnt/β-catenin signaling and disease. Cell 149, 1192–1205 [DOI] [PubMed] [Google Scholar]
  • 36. Kuroda S., Fukata M., Nakagawa M., Fujii K., Nakamura T., Ookubo T., Izawa I., Nagase T., Nomura N., Tani H., Shoji I., Matsuura Y., Yonehara S., Kaibuchi K. (1998) Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion. Science 281, 832–835 [DOI] [PubMed] [Google Scholar]
  • 37. Briggs M. W., Li Z., Sacks D. B. (2002) IQGAP1-mediated stimulation of transcriptional co-activation by β-catenin is modulated by calmodulin. J. Biol. Chem. 277, 7453–7465 [DOI] [PubMed] [Google Scholar]
  • 38. Sharma S., Findlay G. M., Bandukwala H. S., Oberdoerffer S., Baust B., Li Z., Schmidt V., Hogan P. G., Sacks D. B., Rao A. (2011) Dephosphorylation of the nuclear factor of activated T cells (NFAT) transcription factor is regulated by an RNA-protein scaffold complex. Proc. Natl. Acad. Sci. U.S.A. 108, 11381–11386 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Kim J. H., Xu E. Y., Sacks D. B., Lee J., Shu L., Xia B., Kong A. N. (2013) Identification and functional studies of a new Nrf2 partner IQGAP1: a critical role in the stability and transactivation of Nrf2. Antioxid. Redox Signal. 19, 89–101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Goto T., Sato A., Shimizu M., Adachi S., Satoh K., Iemura S., Natsume T., Shibuya H. (2013) IQGAP1 functions as a modulator of dishevelled nuclear localization in Wnt signaling. PLoS One 8, e60865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Johnson M., Sharma M., Brocardo M. G., Henderson B. R. (2011) IQGAP1 translocates to the nucleus in early S-phase and contributes to cell cycle progression after DNA replication arrest. Int. J. Biochem. Cell Biol. 43, 65–73 [DOI] [PubMed] [Google Scholar]
  • 42. Stanisić V., Lonard D. M., O'Malley B. W. (2010) Modulation of steroid hormone receptor activity. Prog. Brain Res. 181, 153–176 [DOI] [PubMed] [Google Scholar]
  • 43. Burns K. A., Li Y., Arao Y., Petrovich R. M., Korach K. S. (2011) Selective mutations in estrogen receptor α D-domain alters nuclear translocation and non-estrogen response element gene regulatory mechanisms. J. Biol. Chem. 286, 12640–12649 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Anbalagan M., Huderson B., Murphy L., Rowan B. G. (2012) Post-translational modifications of nuclear receptors and human disease. Nucl. Recept. Signal. 10, e001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Zhang Y., Li Z., Sacks D. B., Ames J. B. (2012) Structural basis for Ca2+-induced activation and dimerization of estrogen receptor α by calmodulin. J. Biol. Chem. 287, 9336–9344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Kumar R., McEwan I. J. (2012) Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr. Rev. 33, 271–299 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Burns K. A., Korach K. S. (2012) Estrogen receptors and human disease: an update. Arch. Toxicol. 86, 1491–1504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. White C. D., Brown M. D., Sacks D. B. (2009) IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett. 583, 1817–1824 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES